1 / 29

Heart Failure Guidelines

Heart Failure Guidelines. Patrice M. Schneider RN BSN Heart Failure Coordinator South Jersey Heart Group Lourdes Cardiology Services. Background. NHLBI estimates that @ any given time: 35% of pts with heart failure are NYHA I 35% of pts with heart failure are NYHA II

robin-francis
Télécharger la présentation

Heart Failure Guidelines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Heart Failure Guidelines Patrice M. Schneider RN BSN Heart Failure Coordinator South Jersey Heart Group Lourdes Cardiology Services

  2. Background • NHLBI estimates that @ any given time: • 35% of pts with heart failure are NYHA I • 35% of pts with heart failure are NYHA II • 25% of pts with heart failure are NYHA III • 5% of pts with heart failure are NYHA IV • Therefore > 85% pf pts with heart failure are treated primarily in the ambulatory setting

  3. CONGESTIVE HEART FAILUREScope of the Problem in U.S. • Prevalence of CHF: > 3,000,000 in U.S. • Worldwide >15,000,000 • Incidence of CHF: > 400,000/year in U.S. • Most common hospital discharge diagnosis in patients over 65 years old • Mortality of CHF: Approx 200,000/yr in U.S. • Cost of CHF: > $ 7 Billion/yr for Hospital Care • All of above are likely to increase with population aging

  4. Etiology of Heart Failure What causes heart failure? • The loss of a critical quantity of functioning myocardial cells after injury to the heart due to: • Ischemic Heart Disease • Hypertension • Infections (e.g., viral myocarditis, Chagas’ disease) • Toxins (e.g., alcohol or cytotoxic drugs) • Valvular Disease • Prolonged Arrhythmias • Peripartum • Idiopathic Cardiomyopathy

  5. Classification of HF: Comparison Between ACC/AHA HF Stage and NYHA Functional Class A B C D High risk of developing HF Structural heart disease but without symptoms of HF Structural heart disease with HF symptoms, either prior or current Refractory HF requiring specialized interventions I II–III IV Asymptomatic HF No symptoms Mild and Moderate HF Symptoms upon mild to moderate exertion Severe HF Symptomsat rest ACC/AHAHF Stage NYHAFunctionalClass

  6. Challenging Tradition • NYHA class changes over time • Increasing evidence that heart failure is a cellular disease • Despite symptomatic improvement neurohormonal, cytokine and cellular changes continue to occur and allow heart failure to progress • Ejection Fraction (EF) does not correlate with functional capacity (NYHA class)

  7. Classification of HF: Comparison Between ACC/AHA HF Stage and NYHA Functional Class A B C D High risk of developing HF Structural heart disease but without symptoms of HF Structural heart disease with HF symptoms, either prior or current Refractory HF requiring specialized interventions I II–III IV Asymptomatic HF No symptoms Mild and Moderate HF Symptoms upon mild to moderate exertion Severe HF Symptomsat rest ACC/AHAHF Stage NYHAFunctionalClass

  8. Stages of Heart Failure

  9. Evaluation of The Patient With Cardiomyopathy • Historical Data • Etiology • Duration of symptoms • ECG Findings • Biochemical parameters • Levels of various neurohormones • Measurement of effect of NH activation • Hemodynamic parameters • Initial • After tailored therapy • Exercise Capacity • Trends • Risk of sudden deterioration

  10. Insults Ischemia Tachycardia High PVC burden Viral Thyroid disease Unclear etiology Peripartum Idiopathic HIV Infiltrative Hemachromatosis Sarcoidosis amyloid Etiology of Cardiomyopathy • Abnormal loading conditions • Valvular disease • Hypertention • Shunts • Toxins • Chemotherapeutics • Cobalt/heavy metal • Acohol • Genetic • familial • Muscular dystrophies • Mitochondrial disorders • Hypertrophic • ARVD

  11. Historical Data & Prognosis • Duration of illness • Shorter duration of illness associated with a greater likelihood of spontaneous improvement • Patients with recent onset (<6-7 months require close clinical surveillance) • But signs of hemodynamic instability • Or end organ underperfusion Stevenson AM J Med 1987 Steimle JACC 1994

  12. New York Heart Association Functional Classification • I. No limitations of physical activity, no symptoms with ordinary activities • II. Mild/slight limitation, symptoms with ordinary activities • Moderate/marked limitation, symptoms with less than ordinary activities • IV. Severe limitation, symptoms of heart failure at rest • Symptoms: Dyspnea or fatigue Adapted from Criteria Committee of the New York Heart Association, 1994.

  13. Exercise Capacity • NYHA (Gradman Card Clinics 1994) • Annual mortality • NYHA I 5% • NYHA II 3-25 % • NYHA III 10-45% • NYHA IV 50-77% • Some overlap II/III likely related to differences in classification from center to center, subjective interpretation, II, predominantly better than III

  14. Exercise Capacity • 6 minute walk test (6MWT) • Assess day-to-day efforts at submax exertion • Measures distance an individual able to traverse over 6 minute period • In moderate heart failure 6MWT has been shown to be • Inversely related to QOL score • Inversely related to NYHA • Predictive or mortality in moderate HF • In Severe HF (< 300 meters) • Correlate to Peak VO2 • Predictive of 6 month event-free survival • But not long term (>6 month) survival Cahalin Chest 1996

  15. Trends Serial determination of LVEF may enhance prognostic value Mortality @ 1 year < - 5 29% >10 13 % * Prognosis and CMP Survival based on change in EF 1.0 > 10 .50 < - 5 24 48 72 Months V-HeFT I and II data

  16. Prognosis and CMP • Trends • Decrease in EF • Decrease in exercise capacity • Increase in left ventricular diastolic dimension • Risk of sudden Deterioration • Non-revascularizable coronary lesion with a high ischemic burden • Increase in number of arrhythmic events

  17. Treatment Chronic Systolic Heart Failure

  18. Vasodilator Therapy Ace-inhibitors & H/I B-Blockers ARBs Aldosterone Inhibitors DT OHT CRT

  19. Reduction in Mortality with ACE-I & B-Blocker therapy SOLVD II/III CONSENSUS IV MERIT HF II/III US CARVEDILOL II/III COPERNICUS IIIB 40 % 1 yr 34 % 1 yr 65% ½ yr 35% 10 mos 16% 3 yr B-Blocker ACE-I

  20. Which BB should we use? • US CARVEDILOL Trial • Coreg • Target 25 mg bid • Caveats • > 70 kg: 50 mg bid • Able to decrease vasodilator to allow uptitration to maximal dose • MERIT-HF Trial • Metoprolol Succinate • Target: 150 mg daily • Caveat • Metoprolol Tartrate is inferior (however it was underdosed in the trial) • CIBIS II Trial • Bisoprolol • Target: approximately 7.5 mg daily • Asthmatics

  21. Changes in LVEF Cardiovascular hospitalizations  0.4 8 P<.001 P=.01 7  6 0.3  5 Mean number/subject LVEF (EF units) 0.2 4   3  2 0.1 1 0 0 Placebo 6.25 mg bid 12.5 mg bid 25 mg bid Placebo 6.25 mg bid 12.5 mg bid 25 mg bid Carvedilol Carvedilol Carvedilol Dose-Response Trial (MOCHA): Effect on Ejection Fraction and Morbidity Patients receiving diuretics, ACE inhibitors, ± digoxin; follow-up duration 6 months; placebo (n=84), carvedilol (n=261). Adapted from Bristow et al, 1996. P<.05 vs placebo

  22. Mortality in the placebo arm of Val-HeFT by treatment group: 23-month mean follow-up Slide courtesy of J. Cohn

  23. ARBs ELITE II 3152 NYHA III-IV Losartan 50 mg QD vs Capoten 50 mg TID No difference in mortality, well tolerated Pitt et al. Lancet 2000;355;1582-1587 Val-HeFT 5010 NYHA II-IV Valsartan 160 mg BID vs placebo No difference in mortality Significant decrease in morbidity & mortality Cohn et al. NEJM 2001;345:1667-75 Death Hospitalizations for CHF* Cardiac arrest Intravenous therapy Triple therapy adverse effect on mortality CHARM –added 2548 II-IV Candesartan 24 mg QD vs Placebo all on ACE-I Significant decrease in CVd and HF admit McMurray The LANCET 2003:362;767

  24. Where Does Hydralazine/Isosorbide Fit in? • ACE-I or ARB intolerant • ACE-I or ARB are supperior • But if intolerant due to • Cough • Hyperkalemia, renal insufficiency • Angioedema • BIDIL (V-HeFT Trial) • AA who still have NYHA II-IV HF despite • ACE/ARB and BB • ON TOP of baseline therapy, not instead of • 3 times a day

  25. RALES Trial 1663 NYHA III-IV 25 mg Aldactonevs Placebo 30% reduction in death* Progressive HF SCD 35% reduction in hospitalization Significant improvement in NYHA functional class Pitt et al. NEJM 1999;341:709 EPHESUS Trial 6632 pts 3-14 d after AMI, EF < 40% And sign of HF Or DM with or without signs of HF 50 mgQDEplerenonevs placebo Significant reduction in: Death 14 % v 17% CVd/hosp 27% v 30% SCD 4.9% vs 6% Pitt NEJM 2003;348:1309 Aldosterone Inhibitors

  26. Sinus node AV node Stimulation therapy Ventricular Resynchronization • Ventricular dyssynchrony • 30 - 50% CHF patients with IVCD • As QRS widens • Mortality increases • Electrical delay translates to mechanical delay/dyssynchrony • Improved • A-V synchrony • Interventricular synchrony • Intraventricular synchrony • Positive remodeling • Reduction in heart failure and all-cause morbidity and mortality Conduction block Abraham WT and Hayes DL, Circulation 2003; 108:2596-2603

  27. Chronic Heart Failure • NYHA I • ACE-inhibitor- SOLVD Prevention Trial • NYHA II/III • ACE-I – SOLVD, V-HeFT II • Hydralazine/ISDN – V-HeFT • B-Blocker – MERIT-HF, US Carvedilol, • Angiotensin Receptor Blocker- Val-HeFT, CHARM • NYHA IV • ACE-I- CONSENSUS • B-Blocker- COPERNICUS • NYHA III/IV • Aldosterone Blocker – RALES • Resynchronization therapy (EF <35%, QRS > 130ms) • Post-AMI • ACE-I SAVE Trial • B-Blocker CAPRICORN Trial • Eplerenone EPHESUS Trial

  28. Mechanism of Death in HF Other 11% Other 15% Other 24% SCD 33% SCD 59% SCD 64% HF 26% HF 12% HF 56% NYHA IV NYHA II NYHA III HF = mortality secondary to worsening heart failure SCD = sudden cardiac death MERIT-HF Study Group. Lancet 1999

  29. Ultimate Goal Delay progression of heart failure or death to the point where good quality and quantity of life is achieved

More Related